Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionEES - WisdomTree U.S. SmallCap Fund N/A
Latest Disclosed Ownership69,208 shares
Latest Disclosed Value $ 1,713,590
EES - WisdomTree U.S. SmallCap Fund N/A reports 1.81% decrease in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On June 1, 2026 - EES - WisdomTree U.S. SmallCap Fund N/A filed a NPORT-P form disclosing ownership of 69,208 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $1,713,590 USD as of March 31, 2026. The entity filed a previous NPORT-P on February 27, 2026 disclosing 70,481 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of -1.81% during the quarter. The current value of the position is $2,179,360 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-06-01 2026-03-31 NP Catalyst Pharmaceuticals Inc. COM EC US14888U1016 69,208 -1,273 -1.81 1,714 4.13 0.2707
2026-02-27 2025-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 70,481 10,735 17.97 1,645 39.88 0.2609
2025-11-25 2025-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 59,746 -150 -0.25 1,177 -9.47 0.1877
2025-08-29 2025-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 59,896 -869 -1.43 1,300 -11.81 0.2224
2025-05-30 2025-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 60,765 410 0.68 1,474 17.00 0.2572
2025-02-28 2024-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 60,355 26,029 75.83 1,260 84.60 0.1957
2024-11-27 2024-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 34,326 -1,220 -3.43 682 24.00 0.1079
2024-08-28 2024-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 35,546 -818 -2.25 551 -5.01 0.0938
2024-05-21 2024-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 36,364 -986 -2.64 580 -7.66 0.0893
2024-02-29 2023-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 37,350 10,365 38.41 628 99.05 0.0949
2023-11-27 2023-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 26,985 1,386 5.41 315 -8.43 0.0536
2023-08-29 2023-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 25,599 -695 -2.64 344 -20.92 0.0594
2023-05-30 2023-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 26,294 -3,373 -11.37 436 -21.05 0.0761
2023-02-28 2022-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 29,667 -47,857 -61.73 552 -44.57 0.0867
2022-11-09 2022-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 77,524 2,541 3.39 995 89.33 0.1841
2022-08-29 2022-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 74,983 -6,189 -7.62 526 -21.87 0.0956
2022-05-17 2022-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 81,172 8,159 11.17 673 36.03 0.0971
2022-02-28 2021-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 73,013 -166,106 -69.47 494 -61.01 0.0740
2021-11-09 2021-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 239,119 -3,881 -1.60 1,267 -9.31 0.2125
2021-08-26 2021-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 243,000 -6,771 -2.71 1,397 21.37 0.2256
2021-05-10 2021-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 249,771 13,599 5.76 1,151 46.07 0.1890
2021-02-26 2020-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 236,172 216,747 1,115.81 789 1,282.46 0.1663
2020-11-12 2020-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 19,425 -2,079 -9.67 58 -42.42 0.0152
2020-08-28 2020-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 21,504 -7,259 -25.24 99 -10.00 0.0249
2020-05-11 2020-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 28,763 -4,312 -13.04 111 -11.29 0.0264
2020-03-02 2019-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 33,075 33,075 124 0.0149
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.